Exact Mass: 477.3242768
Exact Mass Matches: 477.3242768
Found 222 metabolites which its exact mass value is equals to given mass value 477.3242768
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Gentamicin
A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1(subA), obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation). [PubChem] D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06A - Antibiotics for topical use S - Sensory organs > S03 - Ophthalmological and otological preparations > S03A - Antiinfectives > S03AA - Antiinfectives J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins S - Sensory organs > S02 - Otologicals > S02A - Antiinfectives > S02AA - Antiinfectives C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors C254 - Anti-Infective Agent > C258 - Antibiotic
LysoPE(0:0/18:2(9Z,12Z))
C23H44NO7P (477.28552440000004)
LysoPE(0:0/18:2(9Z,12Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/18:2(9Z,12Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(18:2/0:0)
C23H44NO7P (477.28552440000004)
LysoPE(18:2(9Z,12Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(18:2(9Z,12Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
(5Z)-7-[(1R)-2-[(1E,3S)-3-Hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine
C27H43NO6 (477.30902180000004)
(5Z)-7-[(1R)-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R)-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R)-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-[(1R)-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z)-7-[(1R,2E,5S)-5-Hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine
C27H43NO6 (477.30902180000004)
(5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z)-7-{2-[(1E,3R)-3-Hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoylcarnitine
C27H43NO6 (477.30902180000004)
(5Z)-7-{2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-{2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-{2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-{2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Etimicin
VAPIPROST
C30H39NO4 (477.28789340000003)
Phosphatidylethanolamine lyso 18:2
C23H44NO7P (477.28552440000004)
(-)-PF1163A|(3S,10R,13S)-3-(4-(2-hydroxyethoxy)benzyl)-13-((S)-2-hydroxypentyl)-4,10-dimethyl-1-oxa-4-azacyclotridecane-2,5-dione|(3S,10R,13S)-3-[4-(2-hydroxyethoxy)benzyl]-13-[(S)-2-hydroxypentyl]-4,10-dimethyl-1-oxa-4-azacyclotridecane-2,5-dione|PF 1163A|PF1163A
C27H43NO6 (477.30902180000004)
LPE 18:2
C23H44NO7P (477.28552440000004)
Annotation level-3
((4R)-4-((3R,5S,7R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2,2-dimethylpentanoyl)glycine
Ala Phe Ile Lys
Ala Phe Lys Ile
Ala Phe Lys Leu
Ala Phe Leu Lys
Ala Ile Phe Lys
Ala Ile Lys Phe
Ala Lys Phe Ile
Ala Lys Phe Leu
Ala Lys Ile Phe
Ala Lys Leu Phe
Ala Leu Phe Lys
Ala Leu Lys Phe
Phe Ala Ile Lys
Phe Ala Lys Ile
Phe Ala Lys Leu
Phe Ala Leu Lys
Phe Ile Ala Lys
Phe Ile Lys Ala
Phe Lys Ala Ile
Phe Lys Ala Leu
Phe Lys Ile Ala
Phe Lys Leu Ala
Phe Leu Ala Lys
Phe Leu Lys Ala
Ile Ala Phe Lys
Ile Ala Lys Phe
Ile Phe Ala Lys
Ile Phe Lys Ala
Ile Lys Ala Phe
Ile Lys Phe Ala
Lys Ala Phe Ile
Lys Ala Phe Leu
Lys Ala Ile Phe
Lys Ala Leu Phe
Lys Phe Ala Ile
Lys Phe Ala Leu
Lys Phe Ile Ala
Lys Phe Leu Ala
Lys Ile Ala Phe
Lys Ile Phe Ala
Lys Leu Ala Phe
Lys Leu Phe Ala
Leu Ala Phe Lys
Leu Ala Lys Phe
Leu Phe Ala Lys
Leu Phe Lys Ala
Leu Lys Ala Phe
Leu Lys Phe Ala
gentamicin
D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06A - Antibiotics for topical use S - Sensory organs > S03 - Ophthalmological and otological preparations > S03A - Antiinfectives > S03AA - Antiinfectives J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins S - Sensory organs > S02 - Otologicals > S02A - Antiinfectives > S02AA - Antiinfectives C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors C254 - Anti-Infective Agent > C258 - Antibiotic
PC(O-16:2/0:0)[U]
Oleyloxyethyl Phosphorylcholine
C25H52NO5P (477.35829120000005)
PE(18:2(9Z,12Z)/0:0)
C23H44NO7P (477.28552440000004)
P-Decyloxybenzylidene p-Aminocinnamic Acid l-2-Methylbutyl Ester
(S)-(+)-NALPHA-BENZYL-NBETA-BOC-L-HYDRAZINOALANINE DICYCLOHEXYLAMINE SALT
Gentamycin C1
D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06A - Antibiotics for topical use S - Sensory organs > S03 - Ophthalmological and otological preparations > S03A - Antiinfectives > S03AA - Antiinfectives J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins S - Sensory organs > S02 - Otologicals > S02A - Antiinfectives > S02AA - Antiinfectives D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors
(3S,10R,13S)-3-[[4-(2-hydroxyethoxy)phenyl]methyl]-13-[(2S)-2-hydroxypentyl]-4,10-dimethyl-1-oxa-4-azacyclotridecane-2,5-dione
C27H43NO6 (477.30902180000004)
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] octadeca-9,12-dienoate
C23H44NO7P (477.28552440000004)
1-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine
C23H44NO7P (477.28552440000004)
Hentriaconta-3,6,9,12,19,22,25,28-octaene-16-one-15-oate
[(2R)-2,3-dihydroxypropyl] 2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]ethyl hydrogen phosphate
C23H44NO7P (477.28552440000004)
(E)-7-[3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid
C30H39NO4 (477.28789340000003)
2-[(E)-2-amino-1,3-dihydroxyoctadec-4-enyl]-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
(5Z)-7-[(1R)-2-[(1E,3S)-3-Hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine
C27H43NO6 (477.30902180000004)
(5Z)-7-[(1R,2E,5S)-5-Hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine
C27H43NO6 (477.30902180000004)
(5Z)-7-{2-[(1E,3R)-3-Hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoylcarnitine
C27H43NO6 (477.30902180000004)
2-azaniumylethyl (2R)-3-hydroxy-2-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propyl phosphate
C23H44NO7P (477.28552440000004)
[(1S)-7-methoxy-2-[(2-methoxyphenyl)methyl]-9-methyl-1-propyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
(E)-7-[(1R,2R,3S,5S)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid
C30H39NO4 (477.28789340000003)
(3R,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one
(3R,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one
(3R,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one
(3S,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one
(3R,9R,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one
(3S,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one
(3R,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one
(3S,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one
[(1S)-2-(cyclopropylmethyl)-1-[(4-fluorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
((4R)-4-((3R,5S,7R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2,2-dimethylpentanoyl)glycine
N-hexanoylsphingosine 1-phosphate
A ceramide 1-phosphate in which the ceramide N-acyl group is specified as hexanoyl.
(2S,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]-2-oxanyl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9Z,12Z)-octadeca-9,12-dienoate
C23H44NO7P (477.28552440000004)
[3-[(9Z,12Z)-hexadeca-9,12-dienoxy]-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-aminoethyl [2-hydroxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propyl] hydrogen phosphate
(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)dodec-4-ene-1-sulfonic acid
C24H47NO6S (477.31239220000003)
3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]dodecane-1-sulfonic acid
C24H47NO6S (477.31239220000003)
3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]decane-1-sulfonic acid
C24H47NO6S (477.31239220000003)
3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]undecane-1-sulfonic acid
C24H47NO6S (477.31239220000003)
(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)undec-4-ene-1-sulfonic acid
C24H47NO6S (477.31239220000003)
(E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)dec-4-ene-1-sulfonic acid
C24H47NO6S (477.31239220000003)
3-Hydroxy-2-(tetradecanoylamino)undecane-1-sulfonic acid
C25H51NO5S (477.34877560000007)
2-(Decanoylamino)-3-hydroxypentadecane-1-sulfonic acid
C25H51NO5S (477.34877560000007)
3-Hydroxy-2-(undecanoylamino)tetradecane-1-sulfonic acid
C25H51NO5S (477.34877560000007)
2-(Dodecanoylamino)-3-hydroxytridecane-1-sulfonic acid
C25H51NO5S (477.34877560000007)
3-Hydroxy-2-(tridecanoylamino)dodecane-1-sulfonic acid
C25H51NO5S (477.34877560000007)
3-Hydroxy-2-(pentadecanoylamino)decane-1-sulfonic acid
C25H51NO5S (477.34877560000007)
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (6E,9E)-octadeca-6,9-dienoate
C23H44NO7P (477.28552440000004)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] acetate
C23H44NO7P (477.28552440000004)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9E,12E)-octadeca-9,12-dienoate
C23H44NO7P (477.28552440000004)
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9E,12E)-octadeca-9,12-dienoate
C23H44NO7P (477.28552440000004)
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (2E,4E)-octadeca-2,4-dienoate
C23H44NO7P (477.28552440000004)
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9E,11E)-octadeca-9,11-dienoate
C23H44NO7P (477.28552440000004)
2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxydodeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)trideca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(butanoylamino)-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-acetamido-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
1-Linoleoyl-sn-glycero-3-phosphoethanolamine
C23H44NO7P (477.28552440000004)
A 1-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as linoleoyl.
1-linoleoyl-sn-glycero-3-phosphoethanolamine zwitterion
C23H44NO7P (477.28552440000004)
A lysophosphatidylethanolamine zwitterion obtained by transfer of a proton from the phosphate group to the amino group of 1-linoleoyl-sn-glycero-3-phosphoethanolamine. Major species at pH 7.3.
2-linoleoyl-sn-glycero-3-phosphoethanolamine
C23H44NO7P (477.28552440000004)
A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as linoleoyl.
1-(1Z,12Z-nonadecadienyl)-sn-glycero-3-phosphoethanolamine
lysophosphatidylcholine 15:2
C23H44NO7P (477.28552440000004)
A lysophosphatidylcholine in which the remaining acyl group (position unspecified) contains 15 carbons and 2 double bonds.
lysophosphatidylethanolamine 18:2
C23H44NO7P (477.28552440000004)
A lysophosphatidylethanolamine in which the acyl group (position not specified) contains 18 carbons and 2 double bonds.
lysophosphatidylethanolamine (18:2/0:0)
C23H44NO7P (477.28552440000004)
A lysophosphatidylethanolamine 18:2 in which the acyl group is located at position 1.
lysophosphatidylethanolamine (0:0/18:2)
C23H44NO7P (477.28552440000004)
A lysophosphatidylethanolamine 18:2 in which the acyl group is located at position 2.
PF 1163A
C27H43NO6 (477.30902180000004)
A macrolide antibiotic that is 4,10-dimethyl-1-oxa-4-azacyclotridecane-2,5-dione substituted by a 4-(2-hydroxyethoxy)benzyl group at position 3 and a (2R)-2-hydroxypentyl group at position 13 (the 3S,10R,13S stereoisomer). It is isolated from Penicillium sp.PF1163 and exhibits antifungal activity against the pathogenic fungal strain Candida albicans TIMM1768.
2-linoleoyl-sn-glycero-3-phosphoethanolamine zwitterion
C23H44NO7P (477.28552440000004)
A 2-acyl-sn-glycero-3-phosphoethanolamine zwitterion obtained by transfer of a proton from the phosphate to the amino group of 2-linoleoyl-sn-glycero-3-phosphoethanolamine; major species at pH 7.3.
PE(18:2)
C23H44NO7P (477.28552440000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LPC(16:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1SPH(18:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
11-ethyl-4,6,8,16-tetramethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate
C27H43NO6 (477.30902180000004)
2-{2-[(1-hydroxyethylidene)amino]-n,3-dimethylpentanamido}-3-(4-hydroxyphenyl)-n-(1-methoxy-4-methyl-1-oxopentan-2-yl)propanimidic acid
(3s,6s)-3-{[5,7-bis(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-6-(hydroxymethyl)-3,6-dihydropyrazine-2,5-diol
(3s,6s)-3-[(r)-[6,7-bis(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl](hydroxy)methyl]-6-methyl-3,6-dihydropyrazine-2,5-diol
1-[(1s,3as,3br,5as,7s,9as,9bs,11ar)-7-{[(2r,4r,5r,6r)-5-amino-4-methoxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]ethanone
(1s,2r,3r,4s,5r,6s,8r,9r,10r,13r,16s,17r,18r)-11-ethyl-4,6,8,16-tetramethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate
C27H43NO6 (477.30902180000004)
(3s,3ar,4s,6as,10s,12s,15r,15as)-3-benzyl-1-hydroxy-5-(hydroxymethyl)-4,10,12-trimethyl-3h,3ah,4h,6ah,9h,10h,11h,12h,15h-cycloundeca[d]isoindol-15-yl acetate
C30H39NO4 (477.28789340000003)
3-{[7-(4-hydroxy-3-methylbut-2-en-1-yl)-5-(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
3-{[5,7-bis(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-6-(hydroxymethyl)-3,6-dihydropyrazine-2,5-diol
(3s,6s)-3-({7-[(2z)-4-hydroxy-3-methylbut-2-en-1-yl]-5-(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methyl)-6-methyl-3,6-dihydropyrazine-2,5-diol
3-benzyl-1,6-dihydroxy-4,10,12-trimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,12h,15h-cycloundeca[d]isoindol-15-yl acetate
C30H39NO4 (477.28789340000003)
3-{[4-(2-hydroxyethoxy)phenyl]methyl}-13-(2-hydroxypentyl)-4,10-dimethyl-1-oxa-4-azacyclotridecane-2,5-dione
C27H43NO6 (477.30902180000004)
(3s,3ar,4s,6as,10s,12r,15r,15as)-3-benzyl-1,12-dihydroxy-4,5,10,12-tetramethyl-3h,3ah,4h,6ah,9h,10h,11h,15h-cycloundeca[d]isoindol-15-yl acetate
C30H39NO4 (477.28789340000003)
3-{[6,7-bis(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl](hydroxy)methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
1-[(1r,3as,3br,5as,7s,9as,9bs,11ar)-7-{[(2r,4s,5r,6r)-5-amino-4-methoxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]ethanone
(3s,10r,13s)-3-{[4-(2-hydroxyethoxy)phenyl]methyl}-13-[(2s)-2-hydroxypentyl]-4,10-dimethyl-1-oxa-4-azacyclotridecane-2,5-dione
C27H43NO6 (477.30902180000004)